Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs

European Journal of Endocrinology

Volumn 171, Issue 5, 2014, Pages 545-554

  Araujo, Susana ^a   Bañón, Sara ^a   Machuca, Isabel ^a   Moreno, Ana ^a   Pérez Elías, María J ^a   Casado, José L ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DIABETES MELLITUS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT IDENTIFICATION; RISK ASSESSMENT; WAIST HIP RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PREVALENCE; RISK FACTOR;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIABETES MELLITUS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84910128099     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0337     Document Type: Article

References (59)

1. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N et al. All-cause mortality in treated HIV-infected adults with CD4 ≥ 500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. International Journal of Epidemiology 2012 41 433-445. (doi:10.1093/ije/dyr164)
2. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A & Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clinical Infectious Diseases 2011 53 1120-1126. (doi:10.1093/cid/cir627)
3. Calmy A, Hirschel B, Cooper DA & Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007 370 12-14. (doi:10.1016/S0140-6736(07)61027-7)
4. Visnegarwala F, Chen L, Raghavan S & Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. Journal of Infection 2005 50 331-337. (doi:10.1016/j.jinf.2004.06.001)
5. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chene G et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012 26 303-314. (doi:10.1097/QAD.0b013e32834e8776)
6. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2009 50 499-505. (doi:10.1097/QAI.0b013e31819c291b)
7. Arama V, Tiliscan C, Streinu-Cercel A, Ion D, Mihailescu R, Munteanu D, Hristea A, Arama SS & group S-As . Insulin resistance and adipokines serum levels in a caucasian cohort of HIV-positive patients undergoing antiretroviral therapy: a cross sectional study. BMC Endocrine Disorder 2013 13 4. (doi:10.1186/1472-6823-13-4)
8. Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, Bouchaud O, Capeau J, Meyer L, Vigouroux C et al. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antiviral Therapy 2012 17 91-100. (doi:10.3851/IMP1916)
9. Calza L,Manfredi R& Chiodo F. Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy. Metabolic Syndrome and Related Disorders 2004 2 241-250. (doi:10.1089/met.2004.2.241)
10. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW & Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism 2003 88 627-636. (doi:10.1210/jc.2002-020795)
11. Blumer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P & Sauerwein HP. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008 22 227-236. (doi:10.1097/QAD.0b013e3282f33557)
12. Dave JA, Lambert EV, Badri M, West S, Maartens G & Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2011 57 284-289. (doi:10.1097/QAI.0b013e318221863f)
13. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P & Portier H. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001 27 245-250. (doi:10.1097/00126334-200107010-00005)
14. van Vonderen MG, Blumer RM, Hassink EA, Sutinen J, Ackermans MT, van Agtmael MA, Yki-Jarvinen H, Danner SA, Serlie MJ, Sauerwein HP et al. Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2010 53 186-193. (doi:10.1097/QAI. 0b013e3181c190f4)
15. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M & Justman JE. Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. Journal of Acquired Immune Deficiency Syndromes 2008 49 369-376. (doi:10.1097/QAI.0b013e318189a780)
16. Freitas P, Carvalho D, Santos AC, Mesquita J, Matos MJ, Madureira AJ, Martinez E, Sarmento A & Medina JL. Lipodystrophy defined by fat mass ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance. BMC Infectious Diseases 2012 12 180. (doi:10.1186/1471-2334-12-180)
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
18. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T & Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000 23 57-63. (doi:10.2337/diacare.23.1.57)
19. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R & Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 1963-1972. (doi:10.2337/dc06-9912)
20. Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P, Ruidavets JB, Drouet L & Ferrieres J. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002 25 1371-1377. (doi:10.2337/ diacare.25.8.1371)
21. Ben-Romano R, Rudich A, Torok D, Vanounou S, Riesenberg K, Schlaeffer F, Klip A & Bashan N. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003 17 23-32. (doi:10.1097/00002030-200301030-00005)
22. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M & Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clinical Infectious Diseases 2006 43 658-660. (doi:10.1086/505974)
23. Palacios R, Merchante N, Macias J, Gonzalez M, Castillo J, Ruiz J, Marquez M, Gomez-Mateos J, Pineda JA & Santos J. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antiviral Therapy 2006 11 529-535.
24. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C & Raghavan SS. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Medicine 2005 6 114-121. (doi:10.1111/j.1468-1293.2005.00273.x)
25. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C & McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010 33 2244-2249. (doi:10.2337/dc10-0633)
26. Limone P, Biglino A, Valle M, Degioanni M, Paola Servato M, Berardi C, Del Rizzo P, Pellissetto C & Carlo Isaia G. Insulin resistance in HIVinfected patients: relationship with pro-inflammatory cytokines released by peripheral leukocytes. Journal of Infection 2003 47 52-58. (doi:10.1016/S0163-4453(03)00055-0)
27. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB & Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Archives of Internal Medicine 2005 165 1179-1184. (doi:10.1001/archinte.165.10.1179)
28. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M & Justice AC. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 2004 40 115-119. (doi:10.1002/hep.20289)
29. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clinical Infectious Diseases 2007 45 111-119. (doi:10.1086/518619)
30. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M & Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004 18 641-649. (doi:10.1097/00002030-200403050-00008)
31. Schwarz JM, Lee GA, Park S, Noor MA, Lee J,Wen M, Lo JC, Mulligan K, Schambelan M & Grunfeld C. Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004 18 1852-1854. (doi:10.1097/00002030-200409030-00017)
32. Hruz PW, Murata H, Qiu H & Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002 51 937-942. (doi:10.2337/diabetes.51.4.937)
33. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R & Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998 12 F167-F173. (doi:10.1097/00002030-199815000-00001)
34. Jain RG, Furfine ES, Pedneault L, White AJ & Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Research 2001 51 151-177. (doi:10.1016/S0166-3542(01)00148-6)
35. Janneh O, Hoggard PG, Tjia JF, Jones SP, Khoo SH, Maher B, Back DJ & Pirmohamed M. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antiviral Therapy 2003 8 417-426.
36. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M & Schmidt RE. Impaired glucose tolerance, β cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999 13 F63-F70. (doi:10.1097/00002030-199907090-00001)
37. Carper MJ, Cade WT, Cam M, Zhang S, Shalev A, Yarasheski KE & Ramanadham S. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. American Journal of Physiology. Endocrinology and Metabolism 2008 294 E558-E567. (doi:10.1152/ajpendo.00167.2007)
38. Cheng M, Chen S, Schow SR, Manchem VP, Spevak WR, Cristobal CP, Shi S, Macsata RW, Lum RT, Goldfine ID et al . In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator. Journal of Cellular Biochemistry 2004 92 1234-1245. (doi:10.1002/jcb.20150)
39. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL & Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003 52 918-925. (doi:10.2337/diabetes.52.4.918)
40. Yan Q & Hruz PW. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. Journal of Acquired Immune Deficiency Syndromes 2005 40 398-403. (doi:10.1097/01.qai. 0000176654.97392.c7)
41. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB & Dobs AS. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005 19 1375-1383. (doi:10.1097/01.aids.0000181011.62385.91)
42. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, Fitch K, Thomas BJ, Torriani M, Cote HC et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. American Journal of Physiology. Endocrinology and Metabolism 2007 292 E1666-E1673. (doi:10.1152/ajpendo.00550.2006)
43. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. Journal of Clinical Investigation 2005 115 3587-3593. (doi:10.1172/JCI25151)
44. Randell PA, Jackson AG, Zhong L, Yale K & Moyle GJ. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antiviral Therapy 2010 15 227-233. (doi:10.3851/IMP1518)
45. Bernal E, Masia M, Padilla S, Ramos JM,Martin-Hidalgo A & Gutierrez F. Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir. Medicina Cĺnica 2007 129 252-254. (doi:10.1157/13108348)
46. Shlay JC, Visnegarwala F, Bartsch G, Wang J, Peng G, El-Sadr WM, Gibert C, Kotler D, Grunfeld C, Raghavan S et al . Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. Journal of Acquired Immune Deficiency Syndromes 2005 38 147-155. (doi:10.1097/01.qai.0000143599.64234.15)
47. Busti AJ, Bedimo R,Margolis DM & Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. Journal of Investigative Medicine 2008 56 539-544. (doi:10.231/JIM.0b013e3181641b26)
48. Capel E, Auclair M, Caron-Debarle M & Capeau J. Effects of ritonavirboosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes. Antiviral Therapy 2012 17 549-556. (doi:10.3851/IMP1988)
49. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, Fiedorek FT & Haas DW. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIVseronegative healthy adults. AIDS 2004 18 2137-2144. (doi:10.1097/00002030-200411050-00005)
50. Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R & De La Rosa G. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Research and Human Retroviruses 2012 28 1184-1195. (doi:10.1089/aid.2011.0327)
51. Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A & Diego Miralles G. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Medicine 2009 10 318-327. (doi:10.1111/j.1468-1293.2008.00690.x)
52. Tebas P, Yarasheski K, Henry K, Claxton S, Kane E, Bordenave B, Klebert M & Powderly WG. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Research and Human Retroviruses 2004 20 589-594. (doi:10.1089/ 0889222041217374)
53. Albu JB, Kenya S, He Q, Wainwright M, Berk ES, Heshka S, Kotler DP & Engelson ES. Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. American Journal of Clinical Nutrition 2007 86 100-106.
54. Blass SC, Ellinger S, Vogel M, Ingiliz P, Spengler U, Stehle P, von Ruecker A & Rockstroh JK. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control. European Journal of Medical Research 2008 13 209-214.
55. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, Meigs JB, Sutherland P, D'Agostino RB Sr, O'Donnell CJ et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity 2010 18 2191-2198. (doi:10.1038/oby.2010.59)
56. Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA & Weiel JE. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Research 2000 47 121-129. (doi:10.1016/S0166-3542(00)00102-9)
57. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, de Villar NG, Zabena C, Fernandez C & Serrano-Rios M. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006 55 940-945. (doi:10.1016/j.metabol.2006.02.024)
58. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, Weber K, Piessens E, Robison E & Anastos K. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. Journal of Acquired Immune Deficiency Syndromes 2003 32 298-302. (doi:10.1097/00126334-200303010-00009)
59. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Moller N et al. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Journal of the International AIDS Society 2012 15 17426. (doi:10.7448/IAS.15.2.17426)